The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …

A widespread approach to modern cancer therapy is to identify a single oncogenic driver
gene and target its mutant-protein product (for example, EGFR-inhibitor treatment in EGFR-…

Lung cancer, the leading cause of cancer mortality, exhibits heterogeneity that enables
adaptability, limits therapeutic success, and remains incompletely understood. Single-cell RNA …

Although targeted therapies often elicit profound initial patient responses, these effects are
transient due to residual disease leading to acquired resistance. How tumors transition …

In this study, the impact of the apolipoprotein B mRNA-editing catalytic subunit-like (APOBEC)
enzyme APOBEC3B (A3B) on epidermal growth factor receptor (EGFR)-driven lung …

The strategy for discovery and development of new cancer drugs has shifted the field from
cytotoxic agents to therapies that selectively target oncogenic drivers. In the last decade, a …

Purpose: Although patients with advanced-stage non–small cell lung cancers (NSCLC)
harboring MET exon 14 skipping mutations (METex14) often benefit from MET tyrosine kinase …

ROS1 fusion oncoproteins exhibit differential activation of MAPK signaling according to
subcellular localization, with ROS1 fusions localized to endosomes, the strongest activators of …

… Note: J. Rotow and JD Patel contributed equally as co-senior authors of this article. … Rotow
reports grants, personal fees, and nonfinancial support from Loxo/Lilly, AstraZeneca, and …

… Rotow has served in a consulting or advisory role for AstraZeneca, AbbVie, Gritstone, Lilly,
Takeda, and Sanofi-Genzyme and has received honoraria from AstraZeneca, Pfizer, Merck, …